Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM2 | P31350 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | AGER | Q15109 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13978034 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1MAPTALOX15CYP3A4 | |
| SCHEMBL8487866 | 0.75 | KDM4E (0.46) | KDM4EALDH1A1MAPTALOX15CYP3A4 | |
| SCHEMBL2013556 | 0.75 | KDM4E (0.46) | KDM4EALDH1A1MAPTALOX15CYP3A4 | |
| SCHEMBL25466110 | 0.75 | KDM6B (0.52) | HCAR3KDM4EALDH1A1MAPTALOX15 | |
| SCHEMBL2946120 | 0.75 | DHODH (0.54) | HCAR3KDM4EALDH1A1MAPTALOX15 | |
| SCHEMBL1467625 | 0.74 | MAOA (0.54) | KDM4EALDH1A1MAPTALOX15CYP3A4 | |
| SCHEMBL5515567 | 0.74 | KDM4E (0.47) | KDM4EALDH1A1MAPTALOX15CYP3A4 | |
| SCHEMBL8999006 | 0.73 | RRM2 (0.48) | RRM2KDM4EALDH1A1MAPTL3MBTL1 | |
| SCHEMBL27530818 | 0.73 | RRM2 (0.48) | RRM2KDM4EALDH1A1MAPTCYP3A4 | |
| SCHEMBL15467305 | 0.73 | RRM2 (0.48) | RRM2HCAR3KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466681-A | Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2009-06-24 | — | — | CN | disclosed |
| EP-1996553-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | Avanir Pharmaceuticals (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007109251-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-09-27 | — | — | WO | disclosed |
| US-5364869-A | Treatment of hypertension and congestive heart failure | ABBOTT LABORATORIES (US) | 1994-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | RRM2 1979/4885HCAR3 1559/4885KDM4E 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.